Changes in the Predicted Adult Height after Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic True Precocious Puberty
Annals of Pediatric Endocrinology & Metabolism
;
: 160-168, 2012.
Article
in Korean
| WPRIM
| ID: wpr-132363
ABSTRACT
PURPOSE:
We evaluated the effects of the timing of treatment initiation with gonadotropin-releasing hormone agonist (GnRHa) on the change in predicted adult height (PAH) in girls with idiopathic true precocious puberty (TPP).METHODS:
Data for this retrospective study were collected on 104 girls with TPP who were treated with GnRHa for 36 months, between January 2002 and March 2012.RESULTS:
The PAH SDS differed before and after treatment in all patients (-1.91 +/- 1.47 vs. -1.37 +/- 1.17 after 1 year of treatment, -1.96 +/- 1.58 vs. -0.48 +/- 1.11 after 3 years of treatment) as well as in Group 1 (-2.15 +/- 1.54 vs. -1.51 +/- 1.20 after 1 year of treatment, -2.09 +/- 1.59 vs. -0.55 +/- 1.19 after 3 years of treatment) and Group 2 (-1.57 +/- 1.34 vs. -1.17 +/- 1.12 after 1 year of treatment, -1.50 +/- 1.55 vs. -0.21 +/- 0.74 after 3 years of treatment). This result could be due to improvement in bone age advancement during the treatment. The difference between mid-parental height SDS and PAH SDS was decreased after GnRHa treatment. However, the means of PAH SDS did not surpass the mid-parental height SDS.CONCLUSION:
GnRHa treatment can preserve growth potential by slowing bone age progression, resulting in short adult height, but it cannot alter the genetic growth potential.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Puberty, Precocious
/
Retrospective Studies
/
Gonadotropin-Releasing Hormone
Type of study:
Observational study
/
Prognostic study
Limits:
Adult
/
Humans
Language:
Korean
Journal:
Annals of Pediatric Endocrinology & Metabolism
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS